Viroclinics-DDL, a vaccine and antiviral specialty laboratory providing research and clinical trial solutions rooted in virology, has changed its name to Cerba Research as of April 1, 2024.
 
Viroclinics-DDL, with its three specialty laboratory and office locations in the Netherlands, and an extensive partner laboratory network worldwide, has been part of the Cerba Research group since early 2022. By fully entering into the Cerba Research brand now, the company underscores its collective focus and dedication to the advancement of clinical research together.
 
The name change of Viroclinics-DDL to Cerba Research is designed to mark a step forward in the company’s mission to accelerate the development of life-saving therapies and improve patient outcomes—uniquely positioning Cerba Research to offer a broader portfolio of research and clinical trial solutions spanning virology, oncology, cell & gene therapy, and beyond.
 
The Netherlands business unit combines the strengths and capabilities of existing specialty laboratory services with Cerba Research’s global footprint which includes Africa, USA, Europe, Asia Pacific, and Australia to provide end-to-end support throughout the drug development lifecycle across the globe; from pre-clinical research and biomarker discovery to clinical trial management and epidemiological studies.